Bioresorbable Medical Material Market Report 2026

The bioresorbable medical material market size has grown strongly in recent years. It will grow from $1.71 billion in 2025 to $1.88 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to growing use of biodegradable polymers in medical devices, increasing surgical implant procedures, rising demand for minimally invasive treatments, advancements in polymer chemistry, expansion of biomedical research activities.

The bioresorbable medical material market size is expected to see rapid growth in the next few years. It will grow to $2.77 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing adoption of regenerative medicine solutions, rising demand for next-generation implant materials, expansion of personalized medical devices, growing investments in tissue engineering technologies, increasing focus on reducing secondary surgeries. Major trends in the forecast period include increasing adoption of bioresorbable polymer implants, rising use of temporary medical implants, growing demand for advanced tissue engineering scaffolds, expansion of drug-eluting bioresorbable devices, enhanced focus on controlled degradation materials.

The rising number of surgical procedures is anticipated to drive the growth of the bioresorbable medical material market in the coming years. Surgical procedures involve medical treatments that require making an incision and using instruments to treat or repair diseases in a living body. Bioresorbable polymers are utilized in molded medical devices, especially in neurology, orthopedics, and cosmetic surgery. These materials are commonly used to manufacture sutures, anchors, and screws. For example, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based organization, reported that aesthetic procedures reached nearly 35 million in 2023, with the total number of surgical and non-surgical procedures increasing by 3.4% to 34.9 million. Hence, the growing number of surgeries is contributing to the expansion of the bioresorbable medical material market.

Key companies in the bioresorbable medical material market are concentrating on developing innovative biomaterials for 3D printing applications to maintain their competitive edge. Novel biomaterials are advanced, bioresorbable substances designed to safely degrade in the body while supporting the creation of high-performance medical devices. For instance, in September 2023, Zeus Industrial Products, Inc., a US-based firm specializing in advanced polymer solutions, launched next-generation tubing for bioresorbable vascular scaffolds called Absorv XSE. This product enhances the performance of vascular treatment devices by offering extensive customization across polymer types and sizes, allowing tailored mechanical and absorption properties. Absorv XSE ensures improved wall-thickness uniformity for consistent production and provides approximately 25% more usable scaffolds after laser cutting compared to previous versions.

In April 2024, ProMed Pharma, a US-based contract manufacturer specializing in polymer-based drug-releasing dosage forms and combination device components, acquired SpineThera for an undisclosed amount. This acquisition is intended to strengthen ProMed Pharma's market position by enhancing manufacturing capabilities, expanding product offerings, and supporting innovative drug development initiatives. SpineThera is a US-based clinical-stage pharmaceutical company focused on developing innovative injectable drugs, particularly using its proprietary micro-suspension platform technology.

Major companies operating in the bioresorbable medical material market are Johnson & Johnson, Abbott Laboratories, Medtronic PLC, Kureha Corporation, Evonik Industries AG, Stryker Corporation, Toray Industries Inc., Mitsui Chemicals Inc., Arkema S.A., Royal DSM N.V., Zimmer Biomet Holdings Inc., Ashland Global Holdings Inc., Corbion N.V., Zeus Industrial Products Inc., Unitika Ltd., Danimer Scientific, Synbra Technology, KLS Martin Group, Durect Corporation, Putnam Plastics Corporation, Zhejiang Haizheng Biomaterials Co. Ltd., NatureWorks LLC, Foster Corporation, Poly-Med Inc., Futerro S.A., TotalEnergies Corbion B.V.

North America was the largest region in the bioresorbable medical material market in 2025. Asia-Pacific is expected to be the fastest-growing region in the bioresorbable medical material market report during the forecast period. The regions covered in the bioresorbable medical material market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioresorbable medical material market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bioresorbable medical material market by increasing costs of imported specialty polymers, chemical precursors, precision manufacturing equipment, and laboratory instrumentation used in implant and scaffold production. North America and Europe are most affected due to reliance on imported high-purity raw materials, while Asia-Pacific faces cost pressure on export-oriented biomaterial manufacturing. These tariffs are raising production costs and lengthening product development timelines. However, they are also encouraging domestic polymer synthesis, local material processing capabilities, and increased investment in regional biomaterials manufacturing infrastructure.

The bioresorbable medical material market research report is one of a series of new reports that provides bioresorbable medical material market statistics, including bioresorbable medical material industry global market size, regional shares, competitors with a bioresorbable medical material market share, detailed bioresorbable medical material market segments, market trends and opportunities, and any further data you may need to thrive in the bioresorbable medical material industry. This bioresorbable medical material market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bioresorbable medical materials are materials designed to be gradually absorbed or broken down by the body over time. They are utilized in a variety of medical applications, including surgical implants and tissue engineering scaffolds, providing several benefits over permanent implants and removing the need for surgical removal once their intended function is fulfilled.

The primary types of bioresorbable medical materials include polylactic acid (PLA), polyglycolic acid (PGA), polysaccharides, polycaprolactone (PCL), and polylactic-co-glycolic acid (PLGA). Polylactic acid (PLA) is a biodegradable and bioresorbable polymer derived from renewable sources such as corn starch or sugarcane, and it is widely used in bioresorbable medical products, including sutures, screws, and bone fixation devices. These materials find applications in areas such as drug delivery and orthopedics, serving end-users like hospitals and clinics, ambulatory surgical centers, research institutes, and others.

The bioresorbable medical materials market consists of sales of chitosan, collagen, and calcium phosphates. Values in this market are ‘factory gat’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.